251 related articles for article (PubMed ID: 17097285)
1. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
[TBL] [Abstract][Full Text] [Related]
2. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Chen C; Shen HL; Yang J; Chen QY; Xu WL
J Cancer Res Clin Oncol; 2011 Jan; 137(1):9-17. PubMed ID: 20229271
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
6. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
[TBL] [Abstract][Full Text] [Related]
7. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
Sareddy GR; Geeviman K; Ramulu C; Babu PP
J Neurooncol; 2012 Jan; 106(1):99-109. PubMed ID: 21847707
[TBL] [Abstract][Full Text] [Related]
8. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Shishodia S; Aggarwal BB
Cancer Res; 2004 Jul; 64(14):5004-12. PubMed ID: 15256475
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.
Ye CG; Wu WK; Yeung JH; Li HT; Li ZJ; Wong CC; Ren SX; Zhang L; Fung KP; Cho CH
Cancer Lett; 2011 May; 304(2):90-6. PubMed ID: 21377266
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB.
Funakoshi-Tago M; Shimizu T; Tago K; Nakamura M; Itoh H; Sonoda Y; Kasahara T
Biochem Pharmacol; 2008 Sep; 76(5):662-71. PubMed ID: 18644347
[TBL] [Abstract][Full Text] [Related]
13. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer.
Wong BC; Jiang Xh; Fan XM; Lin MC; Jiang SH; Lam SK; Kung HF
Oncogene; 2003 Feb; 22(8):1189-97. PubMed ID: 12606945
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway.
Wang G; Li J; Zhang L; Huang S; Zhao X; Zhao X
Biochem Biophys Res Commun; 2017 Aug; 490(3):969-976. PubMed ID: 28666869
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
16. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
17. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
Ogunwobi OO; Beales IL
Regul Pept; 2006 Mar; 134(1):1-8. PubMed ID: 16169610
[TBL] [Abstract][Full Text] [Related]
18. Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1.
Achari C; Reddy GV; Reddy TC; Reddanna P
Med Chem; 2011 Sep; 7(5):432-42. PubMed ID: 21801152
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.
Kim SH; Song SH; Kim SG; Chun KS; Lim SY; Na HK; Kim JW; Surh YJ; Bang YJ; Song YS
J Cancer Res Clin Oncol; 2004 Sep; 130(9):551-60. PubMed ID: 15197583
[TBL] [Abstract][Full Text] [Related]
20. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
Awara WM; El-Sisi AE; El-Sayad ME; Goda AE
Pharmacol Res; 2004 Nov; 50(5):487-98. PubMed ID: 15458769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
